:Milameline

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = (E)-N-methoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine

| image = Milameline.png

| tradename =

| pregnancy_category =

| legal_status =

| routes_of_administration =

| bioavailability =

| metabolism =

| elimination_half-life =

| excretion =

| IUPHAR_ligand = 301

| CAS_number = 139886-32-1

| ATC_prefix = None

| ATC_suffix =

| PubChem = 9571002

| ChemSpiderID = 7845468

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = R9X77R42FN

| C=8 | H=14 | N=2 | O=1

| smiles = N(/OC)=C\C1=C\CCN(C)C1

}}

Milameline (CI-979, PD-129,409, RU-35,926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.{{cite journal |vauthors=Sedman AJ, Bockbrader H, Schwarz RD | title = Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease | journal = Life Sciences | volume = 56 | issue = 11–12 | pages = 877–882 | year = 1995 | pmid = 10188788 | doi = 10.1016/0024-3205(95)00023-Y}}

• Changing the O-methyl aldoxime to an O-propargyl oxime instead gives a separate molecule called RU 35986.{{cite journal| vauthors = Broadley KJ, Kelly DR |title=Muscarinic Receptor Agonists and Antagonists |journal=Molecules |volume=6 |issue=3 |year=2001 |pages=142–193 |issn=1420-3049 |doi=10.3390/60300142 |pmc=6236374 |doi-access=free }}